Glycemic Control After Antenatal Corticosteroids in Women with Pregestational and Gestational Diabetes
Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Sep 1, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how to better manage blood sugar levels in pregnant women with diabetes who are at risk of giving birth prematurely and are receiving antenatal corticosteroids (ACS). ACS are medications given to help improve the health of babies born early, but they can also affect the mother's blood sugar control. The researchers want to find out which method of managing blood sugar works best after these medications are given. They will compare three different strategies: adjusting insulin doses, adding a sliding scale of insulin, and using a continuous insulin infusion. The ultimate goal is to find the best way to keep mothers' blood sugar levels stable, which could lead to better health outcomes for both mothers and their babies.
To participate in this study, women must be between 18 to 50 years old, have either type 2 diabetes or gestational diabetes that is being treated with insulin or certain oral medications, and be hospitalized to receive ACS due to the risk of preterm birth. The trial is currently recruiting participants who are between 23 weeks and 36 weeks of pregnancy. If eligible, participants can expect to receive care and monitoring related to their blood sugar levels while contributing to important research that could improve care for future mothers and babies facing similar challenges.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Gestational or pregestational type 2 diabetes mellitus treated with daily insulin injection(s) or oral hypoglycemic agents such as metformin
- • Hospitalized for antenatal corticosteroid administration in anticipation of preterm birth
- • Gestational age 23 0/7 weeks - 36 5/7 weeks
- • Maternal age 18-50
- Exclusion Criteria:
- • Planned delivery \< 72 hours after 1st dose of antenatal corticosteroids
- • More than 16 hours after 1st dose of antenatal corticosteroids
- • Major fetal anomaly
- • Triplet or higher order multiple gestation
About University Of Alabama At Birmingham
The University of Alabama at Birmingham (UAB) is a prominent academic institution and research hub dedicated to advancing healthcare through innovative clinical trials. Renowned for its commitment to medical discovery and education, UAB conducts cutting-edge research across a wide array of disciplines, including oncology, cardiology, neurology, and public health. With a robust infrastructure for clinical research, UAB fosters collaboration among interdisciplinary teams, leveraging state-of-the-art facilities and resources to enhance the translation of scientific findings into effective treatments and interventions. As a leader in clinical research, UAB aims to improve patient outcomes and contribute to the broader medical community through rigorous trial design and implementation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Portland, Oregon, United States
Birmingham, Alabama, United States
Houston, Texas, United States
Greenville, South Carolina, United States
Patients applied
Trial Officials
Ashley N Battarbee, MD
Principal Investigator
University of Alabama at Birmingham
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials